The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502).
 
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Hiroyasu Igaki
No Relationships to Disclose
 
Yoshinori Ito
No Relationships to Disclose
 
Isao Nozaki
No Relationships to Disclose
 
Hiroyuki Daiko
No Relationships to Disclose
 
Masahiko Yano
No Relationships to Disclose
 
Masaki Ueno
No Relationships to Disclose
 
Satoru Nakagawa
No Relationships to Disclose
 
Masakazu Takagi
No Relationships to Disclose
 
Shigeru Tsunoda
No Relationships to Disclose
 
Tetsuya Abe
No Relationships to Disclose
 
Tetsu Nakamura
No Relationships to Disclose
 
Jun Hihara
No Relationships to Disclose
 
Yasushi Toh
No Relationships to Disclose
 
Yuichi Shibuya
No Relationships to Disclose
 
Junki Mizusawa
No Relationships to Disclose
 
Hiroshi Katayama
Honoraria - Johnson & Johnson
 
Kenichi Nakamura
Honoraria - Eisai; Merck Serono; Nihonkayaku; Taiho Pharmaceutical
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medicon (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)